| Prev Close | 2.09 |
| Day Low/High | 2.02 / 2.10 |
| 52 Wk Low/High | 1.49 / 7.31 |
| Avg Volume | 36.20K |
Merrimack Pharmaceuticals Inc. (MACK)
2.09
NASDAQ : Health Technology
| Exchange | NASDAQ |
| Shares Outstanding | 13.38M |
| Market Cap | 27.83M |
| EPS | -1.60 |
| P/E Ratio | N/A |
| Div & Yield | N.A. (N.A) |
Latest News
Merrimack Sells Pancreatic Cancer Drug to Ipsen for $1 Billion
Merrimack Pharmaceuticals agreed to sell oncology treatments, including its pancreatic-cancer treatment Onivyde, to French drugmaker Ipsen.
Some 'January Effect' Stock Picks
Small-caps could also benefit from abating tax-loss selling.
Main Biotech Indices Surrender Yesterday's Gains
It was good to stand in for Doug Kass today. Lots of lively conversation this Friday (over 200 comments), most of them around the markets as well....:-). The Daily Diary was certainly more interesting than today's market, which ended mixed as it clo...
Closing Bell: Stocks Close Lower as Utilities Drop, Oil Prices Climb
The first day of trading in the fourth quarter was rough as stocks declined Monday.
Bullish and Bearish Reversals for the Week
Thermo Fisher is looking bullish, while Blue Buffalo goes the other way.
Think Big on These Small Biotechs
New drugs give small-cap companies opportunity to expand markets and revenues.
It's 'All Systems Go' for Biotech
The sector seems to be rebounding after tumbling by more than 40%.
Investors Scour Big Pharma M&A Scene for Next Big Takeover
Following Galenica's $1.5 billion bid for Relypsa, investors are beginning to search for the next target.
More Picks for a Rough Market
Let's look at other attractively valued bets in what is at least a slightly overbought market overall.
Looking Back at Biotech and Housing Small-Caps
I continue to like RLYP, TPH and LGIH.
4 Possible Biotech M&A Targets
These concerns are well on their way to FDA approval for their first commercialized products in addressable markets.
M&A Could Ignite Next Leg Up for Biotech
Pharma and biotech giants now must look to small- and mid-caps to fill out pipelines and bolster growth.
Don't Throw This Biotech 'Baby' Out With the Bathwater
Drug maker Relypsa is poised for a huge upside, despite the current market sentiment.
Don't Throw This Biotech 'Baby' Out With the Bathwater
Drug maker Relypsa is poised for a huge upside, despite the current market sentiment.
A Small Biotech Sells for Less Than Cash
And yet, Endocyte has a deep pipeline.
Cashing In on the Biotech Bear Market
My 4-Tier approach to deploying new capital in the sector.
3 Scorned Biotechs Destined to Rebound
Each of these small-caps delivered good news recently, only to have their stocks decline.
3 Scorned Biotechs Destined to Rebound
Each of these small-caps delivered good news recently, only to have their stocks decline.
Gilead Leads a Biotech Rally
The sector saw solid performance this week as the biotech juggernaut mounted a long-overdue rally.
Gilead Leads a Biotech Rally
The sector saw solid performance this week as the biotech juggernaut mounted a long-overdue rally.
Buy These Biotechs Before They Bounce
Here are some mid-cap names with solid upside potential.
How to Build a Good Foundation in Biotechs
A so-called "pyramid strategy" can help you enter the depressed sector.
Small-Cap Focus: Merrimack Pharmaceuticals
Biotech's pipeline includes a cancer drug that's close to approval.
Looking for Excitement? Look Elsewhere
Maybe earnings reports will rattle the market's cage.
Slow-Motion Rally Continues
The fear in this market is about being left out.
Biotech Stocks With Promise
Allocate to numerous attractive, but speculative positions.
2 Small Cap Biotechs to Bet On
Merrimack and Threshold Pharmaceuticals will soon announce catalysts to propel their stocks, says Rob Goldman of Goldman Small Cap Research.
MACK: What's in the Pipeline
Bob Mulroy, CEO of Merrimack Pharmaceutical, reveals the innovation behind the company's quest to find treatments for cancer.